Selected research
Industry Research
Neurodegenerative Disease Industry Research Report 2026
Market perspective
The global Neurodegenerative Disease market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Neurodegenerative Disease market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Neurodegenerative Disease market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Neurodegenerative Disease market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Neurodegenerative Disease include Biogen Idec, Boehringer Ingelheim, Merck Serono, UCB, BORA PHARMACEUTICALS, Dongcheng Biochemicals, Ark Pharmaceutical, GlaxoSmithKline and Haisco Pharmaceutical, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Neurodegenerative Disease market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Neurodegenerative Disease.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neurodegenerative Disease Market by Company
Biogen Idec
Boehringer Ingelheim
Merck Serono
UCB
BORA PHARMACEUTICALS
Dongcheng Biochemicals
Ark Pharmaceutical
GlaxoSmithKline
Haisco Pharmaceutical
Hisun Pharmaceutical
Huahai Pharmaceutical
Pfizer
Jingxin Pharmaceutical
Kanghong Pharmaceutical
Livzon Pharmaceutical
Luye Pharma
Novartis
Sanofi
TEVA
Neurodegenerative Disease Segment by Type
NMDA
SSRIs
Dopamine Inhibitors
Neurodegenerative Disease Segment by Application
Alzheimer’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Parkinson’s Disease
Neurodegenerative Disease Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Neurodegenerative Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- NMDA
- SSRIs
- Dopamine Inhibitors
Applications
- Alzheimer’s Disease
- Huntington Disease
- Amyotrophic Lateral Sclerosis
- Parkinson’s Disease
Companies covered
- Biogen Idec
- Boehringer Ingelheim
- Merck Serono
- UCB
- BORA PHARMACEUTICALS
- Dongcheng Biochemicals
- Ark Pharmaceutical
- GlaxoSmithKline
- Haisco Pharmaceutical
- Hisun Pharmaceutical
- Huahai Pharmaceutical
- Pfizer
- Jingxin Pharmaceutical
- Kanghong Pharmaceutical
- Livzon Pharmaceutical
- Luye Pharma
- Novartis
- Sanofi
- TEVA
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Neurodegenerative Disease by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 NMDA
- 2.2.3 SSRIs
- 2.2.4 Dopamine Inhibitors
- 2.3 Neurodegenerative Disease by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Alzheimer’s Disease
- 2.3.3 Huntington Disease
- 2.3.4 Amyotrophic Lateral Sclerosis
- 2.3.5 Parkinson’s Disease
- 2.4 Assumptions and Limitations
3 Neurodegenerative Disease Breakdown Data by Type
- 3.1 Global Neurodegenerative Disease Historic Market Size by Type (2021-2026)
- 3.2 Global Neurodegenerative Disease Forecasted Market Size by Type (2027-2032)
4 Neurodegenerative Disease Breakdown Data by Application
- 4.1 Global Neurodegenerative Disease Historic Market Size by Application (2021-2026)
- 4.2 Global Neurodegenerative Disease Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Neurodegenerative Disease Market Perspective (2021-2032)
- 5.2 Global Neurodegenerative Disease Growth Trends by Region
- 5.2.1 Global Neurodegenerative Disease Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Neurodegenerative Disease Historic Market Size by Region (2021-2026)
- 5.2.3 Neurodegenerative Disease Forecasted Market Size by Region (2027-2032)
- 5.3 Neurodegenerative Disease Market Dynamics
- 5.3.1 Neurodegenerative Disease Industry Trends
- 5.3.2 Neurodegenerative Disease Market Drivers
- 5.3.3 Neurodegenerative Disease Market Challenges
- 5.3.4 Neurodegenerative Disease Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Neurodegenerative Disease Players by Revenue
- 6.1.1 Global Top Neurodegenerative Disease Players by Revenue (2021-2026)
- 6.1.2 Global Neurodegenerative Disease Revenue Market Share by Players (2021-2026)
- 6.2 Global Neurodegenerative Disease Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Neurodegenerative Disease Head Office and Area Served
- 6.4 Global Neurodegenerative Disease Players, Product Type & Application
- 6.5 Global Neurodegenerative Disease Manufacturers Established Date
- 6.6 Global Neurodegenerative Disease Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Neurodegenerative Disease Market Size (2021-2032)
- 7.2 North America Neurodegenerative Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Neurodegenerative Disease Market Size by Country (2021-2026)
- 7.4 North America Neurodegenerative Disease Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Neurodegenerative Disease Market Size (2021-2032)
- 8.2 Europe Neurodegenerative Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Neurodegenerative Disease Market Size by Country (2021-2026)
- 8.4 Europe Neurodegenerative Disease Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Neurodegenerative Disease Market Size (2021-2032)
- 9.2 Asia-Pacific Neurodegenerative Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Neurodegenerative Disease Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Neurodegenerative Disease Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Neurodegenerative Disease Market Size (2021-2032)
- 10.2 South America Neurodegenerative Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Neurodegenerative Disease Market Size by Country (2021-2026)
- 10.4 South America Neurodegenerative Disease Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Neurodegenerative Disease Market Size (2021-2032)
- 11.2 Middle East & Africa Neurodegenerative Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Neurodegenerative Disease Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Neurodegenerative Disease Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Biogen Idec
- 12.1.1 Biogen Idec Company Information
- 12.1.2 Biogen Idec Business Overview
- 12.1.3 Biogen Idec Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.1.4 Biogen Idec Neurodegenerative Disease Product Portfolio
- 12.1.5 Biogen Idec Recent Developments
- 12.2 Boehringer Ingelheim
- 12.2.1 Boehringer Ingelheim Company Information
- 12.2.2 Boehringer Ingelheim Business Overview
- 12.2.3 Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.2.4 Boehringer Ingelheim Neurodegenerative Disease Product Portfolio
- 12.2.5 Boehringer Ingelheim Recent Developments
- 12.3 Merck Serono
- 12.3.1 Merck Serono Company Information
- 12.3.2 Merck Serono Business Overview
- 12.3.3 Merck Serono Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.3.4 Merck Serono Neurodegenerative Disease Product Portfolio
- 12.3.5 Merck Serono Recent Developments
- 12.4 UCB
- 12.4.1 UCB Company Information
- 12.4.2 UCB Business Overview
- 12.4.3 UCB Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.4.4 UCB Neurodegenerative Disease Product Portfolio
- 12.4.5 UCB Recent Developments
- 12.5 BORA PHARMACEUTICALS
- 12.5.1 BORA PHARMACEUTICALS Company Information
- 12.5.2 BORA PHARMACEUTICALS Business Overview
- 12.5.3 BORA PHARMACEUTICALS Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.5.4 BORA PHARMACEUTICALS Neurodegenerative Disease Product Portfolio
- 12.5.5 BORA PHARMACEUTICALS Recent Developments
- 12.6 Dongcheng Biochemicals
- 12.6.1 Dongcheng Biochemicals Company Information
- 12.6.2 Dongcheng Biochemicals Business Overview
- 12.6.3 Dongcheng Biochemicals Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.6.4 Dongcheng Biochemicals Neurodegenerative Disease Product Portfolio
- 12.6.5 Dongcheng Biochemicals Recent Developments
- 12.7 Ark Pharmaceutical
- 12.7.1 Ark Pharmaceutical Company Information
- 12.7.2 Ark Pharmaceutical Business Overview
- 12.7.3 Ark Pharmaceutical Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.7.4 Ark Pharmaceutical Neurodegenerative Disease Product Portfolio
- 12.7.5 Ark Pharmaceutical Recent Developments
- 12.8 GlaxoSmithKline
- 12.8.1 GlaxoSmithKline Company Information
- 12.8.2 GlaxoSmithKline Business Overview
- 12.8.3 GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.8.4 GlaxoSmithKline Neurodegenerative Disease Product Portfolio
- 12.8.5 GlaxoSmithKline Recent Developments
- 12.9 Haisco Pharmaceutical
- 12.9.1 Haisco Pharmaceutical Company Information
- 12.9.2 Haisco Pharmaceutical Business Overview
- 12.9.3 Haisco Pharmaceutical Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.9.4 Haisco Pharmaceutical Neurodegenerative Disease Product Portfolio
- 12.9.5 Haisco Pharmaceutical Recent Developments
- 12.10 Hisun Pharmaceutical
- 12.10.1 Hisun Pharmaceutical Company Information
- 12.10.2 Hisun Pharmaceutical Business Overview
- 12.10.3 Hisun Pharmaceutical Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.10.4 Hisun Pharmaceutical Neurodegenerative Disease Product Portfolio
- 12.10.5 Hisun Pharmaceutical Recent Developments
- 12.11 Huahai Pharmaceutical
- 12.11.1 Huahai Pharmaceutical Company Information
- 12.11.2 Huahai Pharmaceutical Business Overview
- 12.11.3 Huahai Pharmaceutical Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.11.4 Huahai Pharmaceutical Neurodegenerative Disease Product Portfolio
- 12.11.5 Huahai Pharmaceutical Recent Developments
- 12.12 Pfizer
- 12.12.1 Pfizer Company Information
- 12.12.2 Pfizer Business Overview
- 12.12.3 Pfizer Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.12.4 Pfizer Neurodegenerative Disease Product Portfolio
- 12.12.5 Pfizer Recent Developments
- 12.13 Jingxin Pharmaceutical
- 12.13.1 Jingxin Pharmaceutical Company Information
- 12.13.2 Jingxin Pharmaceutical Business Overview
- 12.13.3 Jingxin Pharmaceutical Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.13.4 Jingxin Pharmaceutical Neurodegenerative Disease Product Portfolio
- 12.13.5 Jingxin Pharmaceutical Recent Developments
- 12.14 Kanghong Pharmaceutical
- 12.14.1 Kanghong Pharmaceutical Company Information
- 12.14.2 Kanghong Pharmaceutical Business Overview
- 12.14.3 Kanghong Pharmaceutical Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.14.4 Kanghong Pharmaceutical Neurodegenerative Disease Product Portfolio
- 12.14.5 Kanghong Pharmaceutical Recent Developments
- 12.15 Livzon Pharmaceutical
- 12.15.1 Livzon Pharmaceutical Company Information
- 12.15.2 Livzon Pharmaceutical Business Overview
- 12.15.3 Livzon Pharmaceutical Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.15.4 Livzon Pharmaceutical Neurodegenerative Disease Product Portfolio
- 12.15.5 Livzon Pharmaceutical Recent Developments
- 12.16 Luye Pharma
- 12.16.1 Luye Pharma Company Information
- 12.16.2 Luye Pharma Business Overview
- 12.16.3 Luye Pharma Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.16.4 Luye Pharma Neurodegenerative Disease Product Portfolio
- 12.16.5 Luye Pharma Recent Developments
- 12.17 Novartis
- 12.17.1 Novartis Company Information
- 12.17.2 Novartis Business Overview
- 12.17.3 Novartis Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.17.4 Novartis Neurodegenerative Disease Product Portfolio
- 12.17.5 Novartis Recent Developments
- 12.18 Sanofi
- 12.18.1 Sanofi Company Information
- 12.18.2 Sanofi Business Overview
- 12.18.3 Sanofi Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.18.4 Sanofi Neurodegenerative Disease Product Portfolio
- 12.18.5 Sanofi Recent Developments
- 12.19 TEVA
- 12.19.1 TEVA Company Information
- 12.19.2 TEVA Business Overview
- 12.19.3 TEVA Revenue in Neurodegenerative Disease Business (2021-2026)
- 12.19.4 TEVA Neurodegenerative Disease Product Portfolio
- 12.19.5 TEVA Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst